Back to Search Start Over

FDA clears Sanofi's Sarclisa for relapsed refractory multiple myeloma

Source :
NJ Biz. March 2, 2020
Publication Year :
2020

Abstract

Byline: Anthony Vecchione Bridgewater-based Sanofi said March 2 that the U.S. Food and Drug Administration approved Sarclisa in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed [...]

Subjects

Subjects :
United States. Food and Drug Administration
Monoclonal antibodies
Pomalidomide
Recurrence (Disease) -- Drug therapy
Multiple myeloma -- Drug therapy
Drug approval
Antibodies
Dexamethasone
Lenalidomide
Glucocorticoids
Diseases
Business, regional

Details

Language :
English
ISSN :
15404161
Database :
Gale General OneFile
Journal :
NJ Biz
Publication Type :
News
Accession number :
edsgcl.616437921

Tools

Authors Abstract Subjects Details